Quest Diagnostics completed the acquisition of select assets of PathAI Diagnostics from PathAI.

Quest Diagnostics, a diagnostic information services company, completed the acquisition of select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services. Financial terms were not disclosed. "At Quest Diagnostics, we are committed to maximizing patient impact from every precious sample. The relationship with PathAI and acquisition of PathAI Diagnostics will enable us to rapidly accelerate the adoption of digitization and artificial intelligence for our market leading pathology offering, and will therefore strengthen our capability to serve patients across the entire continuum of oncology care, from diagnosis, to prognosis, to therapy selection and patient monitoring," Mark Gardner, Quest Diagnostics Senior Vice President, Molecular Genomics and Oncology.